alexa The Rediscovery Of UPI-928
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd World Congress on Cancer Science & Therapy
October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

John Rothman
ScientificTracks: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.028
Abstract
In the 1980s UPI-928 was developed by a major international pharma. In the early 1990?s with over 40 clinical trials, and a newly grant western European marketing and sales approval the company was sold, and then the purchasing company was sold. UPI-928 was apparently lost in the corporate shuffle and never marketed. As cytotoxic drugs were all that known at the time, UPI-928 was found to have an acceptable tolerability profile in a maximum tolerated dose model of development, and demonstrated efficacy in AML, lymphoma, refractory breast cancer, and ovarian cancer. It was approved for human use for the treatment of AML. Subsequent work has shown that this class of drugs also has various immunogenic and other therapeutic properties, including the up regulation of DAMPs, induction of apoptosis, activation of T cells and myeloid cells, inhibition of HIF-1 expression, and UPI-928 has been found to activate Mφ capable of eliminating tumors in an allogeneic transplant model. Supernatants from activated Mφ were similarly found to be capable of extending survival in allogeneic mice with tumors. More recently, UPI-928 was found to bind to DNA at a specific site that disrupts telomere-telomerase interactions in a manner that dislocates telomerase binding proteins, causing immortalized cells to become senescent and die. UPI-928 may be an agent unique in its abilities to bridge cytotoxic, immune, and genomic mechanisms in a manner that makes it particularly suitable for combinatorial therapy.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]ne.com

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords